Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer

PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth factor receptor 2 (HER2)-type and triple-negative breast cancer (TNBC). We investigated the...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Breast Cancer
Prif Awduron: Kim, Hyung Suk, Yoo, Tae Kyung, Park, Woo Chan, Chae, Byung Joo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Korean Breast Cancer Society 2019
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6769389/
https://ncbi.nlm.nih.gov/pubmed/31598341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2019.22.e35
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg